CT-P51

Phase 3Small molecule

CT-P51 is one of 10 small molecule programs targeting Non-Squamous Non-Small Cell Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Squamous Non-Small Cell Lung CancerActive, not recruiting

Non-Squamous Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Non-Squamous Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Alimta

EEagle Pharmaceuticals, Inc.

Phase 3

6 2

Paraplatin

AAvyxa

Phase 3

6 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

5 4

Alimta

SShawn Eagle

Phase 3

5 5

IBI363

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2

1 6

SKB264

SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2

1 7

CT-P51

CCelltrion

Phase 3

1 8

Beyfortus

BeiGene

Preclinical

1 9

PD-1

SSichuan Baili Pharmaceutical Co., Ltd.

Preclinical

1 10

BL-B01D1

SSichuan Baili Pharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Active, not recruiting

Non-Squamous Non-Small Cell Lung Cancer

NCT06939595

Clinical

Trials by Indication[1]

Non-Squamous Non-Small Cell Lung Cancer1 trial

A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P51 and Keytruda in Combination With Platinum-Pemetrexed Chemotherapy in Patients With Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Active, not recruiting·CCelltrion·Phase 3·NCT06939595·225 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CT-P51. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CT-P51 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CT-P51. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Celltrion company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCelltrion

CT-P51

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Non-Squamous Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News